Using antimicrobial matrices to help heal complex diabetic foot ulcers.
Official title: Antimicrobial dermal matrices to promote infection free wound closure in DTU-DFUs.
Funded at Gel4med, INC. · NIH-10918299 · Data updated 2026-11-12
This study is testing a new treatment called G4Derm for people with severe diabetic foot ulcers, aiming to help these tough wounds heal better and faster while keeping them safe from infections.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Gel4med, INC. NIH-funded |
| Lab location | 1 site (Brighton, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,529,428 |
| NIH project number | 5R44DK137730-02 |
| Project ID | NIH-10918299 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are diabetic patients suffering from advanced foot ulcers that are at risk of infection and complications.
✕Less likely to help
Patients with non-diabetic foot ulcers or those whose wounds are not complex may not benefit from this research.
What this research studies
This research focuses on developing a new treatment for diabetic foot ulcers (DFUs) that have progressed to a more severe stage, known as DTU-DFUs. The approach involves using a biosynthetic product called G4Derm, which is designed to fill complex wounds and promote healing while preventing infections. The product is easy to apply and works by creating a supportive matrix that encourages tissue regeneration. By addressing the challenges of current treatments, this research aims to improve healing outcomes for patients with difficult-to-treat wounds.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of infection and improve healing rates for patients with complex diabetic foot ulcers.
How similar studies have gone: Previous research has shown promising results with similar antimicrobial approaches in wound care, suggesting potential for success in this novel application.
Where this research is happening
-
Gel4med, INC.
Brighton, United States Active
Researchers
- Principal investigator: Mehta, Manav — Gel4med, INC.
- Study coordinator: Mehta, Manav
Related research
Other NIH-funded projects on the same topics.
-
Diabetic Foot Ulcer Healing Network at the University of Arizona
A NIH-supported project at the University of Arizona aims to improve healing of diabetic foot ulcers by studying biomarkers and running high-quality clinical trials.
-
Understanding how skin layers coordinate healing after injury
Researchers are studying how different layers of adult skin coordinate rapid healing after injury to prevent infection and chronic wounds.
-
Immunomodulatory therapy to speed up healing after oral cavity injuries in kids
A new approach using a drug called FTY720 aims to improve healing and reduce pain after oral injuries or palate surgery in children.
-
How diabetic wounds let Group B Streptococcus cause infections
Researchers are learning how high blood sugar, immune changes, and other bacteria in diabetic wounds help Group B Streptococcus grow and cause worse infections in people with diabetes.
-
Understanding how skin cells exchange harmful chemicals to cause injury and wound repair
A research project aims to uncover how certain chemical agents damage human skin and what happens in the early stages of blistering and inflammation.
-
Intestinal mucosal wound healing in humans
A patient-friendly look at how the lining of the gut repairs itself after injury and why this matters for conditions like inflammatory bowel disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.